The study shows how drug-like small molecules inhibit the activity of Transient Receptor Potential Canonical 1/4/5 (TRPC1/4/5) channels and could transform the development of future therapies.
List view / Grid view
Filter the results
According to researchers, the DMBT1S8 molecule can halt inflammation in the respiratory tract through its interaction with the Siglec-8 receptor on immune cells.
A drug screen using machine learning has identified hundreds of potential drugs that could be used to treat COVID-19, researchers say.
A group of German researchers has proposed an empty phage capsid with ligands on its surface as a novel technique to treat influenza.
A group of researchers has synthesised a new class of ligands which bind with high affinity to imidazoline I2 receptors, a drug target for Alzheimer's disease.
Scientists have created an artificial protein able to recognise and bind cell surface carbohydrates with high affinity and selectivity.
Researchers have identified that in leukaemia, mutated receptors allow blood stem cells to activate one another without the proper signal and suggest this discovery could lead to targeted novel therapies.
Research into the structure of the drug-integrin complex has enabled the creation of drugs which inhibit integrin as effectively as currently used compounds, without causing excessive bleeding.
Researchers have slowed the spread of a type of non-small cell lung cancer in mice by neutralising a protein that would otherwise cause tumour growth.
A study has revealed five new signalling processes in GPCR receptors on cells that have high therapeutic potential.
A simple and direct method of introducing lipids into protein has been developed using palladium as a catalyst.
A new drug discovery strategy predicts the clinical actions of new compounds to promote desired clinical responses and avoid side effects.
Application note: Faster and more reliable quantification of oligonucleotide interaction with human serum albumin using MST
Antisense oligonucleotides are an emerging therapeutic option for treating diseases with known genetic origin.
SB Drug Discovery shows the validation of fluorescence and automated electrophysiology assays designed to assess agonists, antagonists and allosteric modulators of these receptors, culminating in a high-throughput electrophysiology assay suited to assessing multiple GABAA receptor subtypes on a single assay plate.